CBD Class-Action Litigants Watching For Retroactive Effects In US FDA’s Awaited Rulemaking
Even in the “highly unlikely event” that the FDA does make CBD supplements legal, it will not do so retroactively, according to plaintiffs against CV Sciences in California’s Central District. However, the federal court, which also is hearing a similar case against competitor Charlotte’s Web, is not convinced.
You may also be interested in...
The Consolidated Appropriations Act, H.R. 133, includes $900bn in unemployment relief to COVID victims as well as regular federal appropriations to avoid a looming government shutdown. US FDA provisions include cosmetics and nutrition industry mentions.
Duffy MacKay, senior VP of scientific and regulatory affairs at CV Sciences, offers his predictions regarding the FDA’s likely course in regulating CBD’s use in dietary supplements – action that is sorely needed as the market continues to crowd with CBD products “with who-knows-what in them.”
Plaintiff Claims Against Beiersdorf For ‘Unlawfully Marketed Drug’ Are Preempted By FDCA, Court Rules
After five and a half years, three dismissal motions and one appeal, Beiersdorf’s prevailed on 15 April by summary judgment in a proposed class action alleging that its Nivea Skin Firming Hydration Body Lotion is an unlawfully marketed drug. Of course, the plaintiff still could appeal.